RecruitingPhase 2NCT06984146
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Enrollment
54 participants
Start Date
Apr 15, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
- No past history of autoimmune disease
- Age \> 18 years
- Ejection fraction \> 50%
- ECOG 0-4
Exclusion Criteria4
- Organ failure (e.g. creatinine \> 2x ULN; ALT or AST \> 5x ULN; bilirubin \> 2x ULN; hemodynamic instability; respiratory failure \> Grade 1)
- Uncontrolled infection
- Pregnancy
- Inability to sign informed consent
Interventions
DRUGNivolumab
40 mg day 1 and 15
DRUGDoxorubicin
25 mg/m2 day 1 and 15
DRUGVinblastine
6 mg/m2 (not exceeding 10 mg) day 1 and 15
DRUGDacarbazine
375 mg/m2 day 1 and 15
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06984146
Related Trials
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT064219871 location
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT057988977 locations
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
NCT046387902 locations
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
NCT0437864719 locations